Consensus CSPC Pharmaceutical Group Limited

Stocks

1093

HK1093012172

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 12:08:08 18/06/2026 +04			5-day change	1st Jan Change
6.890 ^HKD	-0.58%		-4.44%	-18.27%

06-18	CSPC Pharma's Tumor Drug Gets Trial Nod from US FDA	MT
06-18	CSPC Pharma Unit's Marketing Application for Anti-Inflammatory Drug Accepted in China	MT

Evolution of the Average Target: CSPC Pharmaceutical Group Limited

Evolution of the Target Price: CSPC Pharmaceutical Group Limited

Changes in Analyst Recommendations: CSPC Pharmaceutical Group Limited

c2ac7bb3b.KN92fX0ybshnU39dB8e3irTNBaM6E205FTga19rl5pI.YY03OSd2CIAEMQkPVZTT5tebXOlbQlVaUXVrtZeL0_FSkCYKP1MC-TIMTw~e969f9ad866d9ff0f2f9e8bc1b169ac1

Analysts' recommendations: CSPC Pharmaceutical Group Limited

05-28	UOB Kay Hian Downgrades CSPC Pharmaceutical Group to Sell from Hold; Price Target is HK$6	MT
03-26	Jefferies Adjusts CSPC Pharmaceutical Group's Price Target to HK$7.20 From HK$5.90, Keeps at Underperform	MT
02-16	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy	MT
11-21	UOB Kay Hian Downgrades CSPC Pharmaceutical Group to Hold from Buy; Price Target is HK$8.50	MT
11-21	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$9.11 from HK$10.09, Keeps at Buy	MT
20/10/25	CSPC Pharmaceutical says JSKN003 granted breakthrough therapy designation in China	RE
13/10/25	CSPC Pharmaceutical announces NMPA acceptance of new drug application for Efmedaglutide Alfa Injection	RE
09/10/25	CSPC Pharmaceutical's Hypertriglyceridemia Drug Secures FDA Nod for US Trial	MT
25/08/25	Jefferies Adjusts CSPC Pharmaceutical Group's Price Target to HK$5.90 From HK$5, Keeps at Underperform	MT
17/07/25	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.09 From HK$10.22, Keeps at Buy	MT
16/07/25	Macquarie Upgrades CSPC Pharmaceutical Group to Outperform from Neutral; Price Target is HK$10.30	MT
16/06/25	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.22 From HK$8.02, Keeps at Buy	MT
29/05/25	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$8.02 From HK$6.55, Keeps at Buy	MT
31/03/25	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$6.55 From HK$6.48, Keeps at Buy	MT
26/02/25	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$6.48 From HK$7.02, Keeps at Buy	MT
18/11/24	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$7.02 From HK$8.46, Keeps at Buy	MT
22/10/24	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$8.46 From HK$9.29, Keeps at Buy	MT
23/08/24	Zhongtai International Downgrades CSPC Pharmaceutical to Neutral From Buy; Price Target is HK$6.10	MT
22/08/24	Nomura Adjusts CSPC Pharmaceutical's Price Target to HK$9.29 From HK$9.83, Keeps at Buy	MT
22/08/24	Daiwa Securities Downgrades CSPC Pharmaceutical to Neutral From Outperform; Price Target is HK$6	MT
22/08/24	UOB Kay Hian Downgrades CSPC Pharmaceutical to Sell From Buy; Price Target is HK$5	MT
22/08/24	Bank of China International Downgrades CSPC Pharmaceutical to Hold From Buy; Price Target is HK$6.50	MT
23/07/24	Nomura Adjusts CSPC Pharmaceutical's Price Target to HK$9.83 From HK$10.07, Keeps at Buy	MT
28/05/24	Nomura Adjusts CSPC Pharmaceutical’s Price Target to HK$10.07 From HK$9.41, Keeps at Buy	MT
14/03/24	Nomura Adjusts CSPC Pharmaceutical Group’s Price Target to HK$9.41 From HK$8.98, Keeps at Buy	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CSPC PHARMACEUTICAL GROUP LIMITED					+66.79%
	ELI LILLY AND COMPANY					+10.67%
	JOHNSON & JOHNSON					+10.72%
	ABBVIE INC.					+17.12%
	ROCHE HOLDING AG					+12.49%
	ASTRAZENECA PLC					+26.95%
	NOVARTIS AG					+5.39%
	NOVO NORDISK A/S					+11.7%
	AMGEN INC.					+4.49%
	GILEAD SCIENCES, INC.					+27.32%
	Average					+19.36%
	Weighted average by Cap.					+13.16%